Vanguard Group’s Oragenics OGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-2,813
Closed -$532K 4570
2022
Q4
$532K Buy
2,813
+1
+0% +$353 ﹤0.01% 4079
2022
Q3
$1.15M Hold
2,812
﹤0.01% 3960
2022
Q2
$1.75M Hold
2,812
﹤0.01% 3858
2022
Q1
$1.74M Sell
2,812
-13
-0.5% -$9.53K ﹤0.01% 4013
2021
Q4
$2.27M Buy
2,825
+18
+0.6% +$18.2K ﹤0.01% 3991
2021
Q3
$3.21M Buy
2,807
+12
+0.4% +$14.5K ﹤0.01% 3888
2021
Q2
$3.55M Buy
2,795
+284
+11% +$374K ﹤0.01% 3760
2021
Q1
$4.1M Buy
2,511
+1,718
+217% +$3.12M ﹤0.01% 3630
2020
Q4
$641K Buy
793
+3
+0.4% +$2.64K ﹤0.01% 3915
2020
Q3
$818K Buy
790
+149
+23% +$238K ﹤0.01% 3704
2020
Q2
$801K Buy
641
+56
+10% +$55.1K ﹤0.01% 3663
2020
Q1
$611K Buy
585
+11
+2% +$10.6K ﹤0.01% 3628
2019
Q4
$541K Buy
574
+4
+0.7% +$3.57K ﹤0.01% 3779
2019
Q3
$554K Buy
570
+469
+464% +$392K ﹤0.01% 3793
2019
Q2
$89K Buy
101
+12
+13% +$11K ﹤0.01% 4062
2019
Q1
$94K Hold
89
﹤0.01% 4018
2018
Q4
$138K Buy
89
+68
+324% +$133K ﹤0.01% 3948
2018
Q3
$43K Hold
21
﹤0.01% 4132
2018
Q2
$52K Buy
+21
New +$55.2K ﹤0.01% 4096
2018
Q1
Sell
-5
Closed -$22K 4101
2017
Q4
$22K Sell
5
-1
-17% -$6.29K ﹤0.01% 4048
2017
Q3
$45K Hold
6
﹤0.01% 4034
2017
Q2
$39K Sell
6
-5
-45% -$37.1K ﹤0.01% 4038
2017
Q1
$84K Hold
11
﹤0.01% 3996
2016
Q4
$103K Buy
11
+2
+22% +$18.6K ﹤0.01% 3969
2016
Q3
$76K Sell
9
-10
-53% -$120K ﹤0.01% 4003
2016
Q2
$173K Hold
19
﹤0.01% 3969
2016
Q1
$314K Hold
19
﹤0.01% 3879
2015
Q4
$507K Buy
19
+1
+6% +$25K ﹤0.01% 3828
2015
Q3
$528K Buy
18
+4
+29% +$163K ﹤0.01% 3836
2015
Q2
$342K Hold
14
﹤0.01% 3957
2015
Q1
$251K Hold
14
﹤0.01% 3964
2014
Q4
$218K Hold
14
﹤0.01% 3889
2014
Q3
$307K Buy
14
+1
+8% +$29.8K ﹤0.01% 3826
2014
Q2
$469K Hold
13
﹤0.01% 3701
2014
Q1
$655K Buy
13
+1
+8% +$60.7K ﹤0.01% 3578
2013
Q4
$618K Buy
12
+6
+100% +$313K ﹤0.01% 3539
2013
Q3
$296K Hold
6
﹤0.01% 3637
2013
Q2
$319K Buy
+6
New +$340K ﹤0.01% 3572

Other funds holding OGEN

Vanguard Group's OGEN Position: Q1 2023 in Review

Vanguard Group sold out of Oragenics (OGEN) in Q1 2023, closing a stake of 2,813 shares — an estimated $532K sold.

Vanguard Group first reported a position in OGEN in Q2 2013 and held it in 38 quarters. The position peaked at $4.1M in Q1 2021. 10 funds tracked by Wall St. Rank hold OGEN as of Q1 2023.

  • Vanguard Group reported no remaining Oragenics position as of Q1 2023 after selling out during the quarter.
  • Vanguard Group sold 2,813 Oragenics shares in Q1 2023, an estimated $532K.
  • Vanguard Group first reported a position in Oragenics in Q2 2013 and held it in 38 quarters.
  • Vanguard Group's Oragenics position peaked at $4.1M in Q1 2021.
  • 10 funds tracked by Wall St. Rank held Oragenics as of Q1 2023.

Based on Vanguard Group's 13F filing for Q1 2023, filed 15 May 2023.